Viridian Therapeutics (VRDN) director-linked funds receive 32,341 options
Rhea-AI Filing Summary
Viridian Therapeutics director-associated funds received a new stock option grant linked to board service. Investment vehicles managed by Fairmount Funds Management LLC were granted an option covering 32,341 shares of Viridian common stock at an exercise price of $18.48 per share. The option vests in full on the earlier of July 1, 2027 or the company’s 2027 annual meeting of stockholders, if Christopher W. Cain continues serving on Viridian’s Board of Directors. The option expires on July 1, 2036. Under Cain’s arrangement with Fairmount, any net cash or stock from the option must be turned over to the adviser for the benefit of the Fairmount funds, and Cain disclaims beneficial ownership of both the option and the underlying shares.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
CAIN CHRISTOPHER W.
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 32,341 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 32,341 shares (Indirect, See Footnote)
Footnotes (2)
- F1. The option vests in full upon the earlier to occur of (i) July 1, 2027 or (ii) the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continued service on the Board of Directors of the Issuer.
- F2. Under the Reporting Person's arrangement with Fairmount Funds Management LLC (the "Adviser"), the Reporting Person holds the option for one or more investment vehicles managed by the Adviser (each, a "Fairmount Fund"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received from the option for the benefit of such Fairmount Fund. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock.
Key Figures
Option grant size: 32,341 shares
Exercise price: $18.48 per share
Total options after grant: 32,341 options
+2 more
5 metrics
Option grant size
32,341 shares
Stock option covering Viridian common stock
Exercise price
$18.48 per share
Conversion or exercise price of the option
Total options after grant
32,341 options
Total derivative shares following transaction
Option expiration
July 1, 2036
Expiration date of stock option grant
Vesting date trigger
July 1, 2027
Vests on earlier of this date or 2027 annual meeting
Key Terms
Stock Option (Right to Buy), beneficial ownership, annual meeting of stockholders, Board of Directors, +1 more
5 terms
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
beneficial ownership financial
"The Reporting Person therefore disclaims beneficial ownership of the option"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
annual meeting of stockholders financial
"the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continued service"
Board of Directors financial
"continued service on the Board of Directors of the Issuer"
The Board of Directors is a group of people chosen by a company's owners to help make big decisions and oversee how the company is run. They act like a team of advisors or managers, making sure the company stays on track and meets its goals. Their choices can influence the company's success and how it grows.
investment vehicles financial
"the Reporting Person holds the option for one or more investment vehicles managed by the Adviser"
FAQ
What did the latest Form 4 report for Viridian Therapeutics (VRDN)?
The Form 4 reports a grant of a stock option for 32,341 Viridian Therapeutics (VRDN) shares. The option is linked to director Christopher W. Cain’s board service but is held for investment vehicles managed by Fairmount Funds Management LLC, which benefit from any net proceeds.
What is the exercise price and expiration date of the new VRDN option?
The option has an exercise price of $18.48 per Viridian Therapeutics (VRDN) share and expires on July 1, 2036. This gives the Fairmount-managed investment vehicles a long-dated right to buy shares if the vesting and service conditions are satisfied over time.
When does the new Viridian Therapeutics (VRDN) option vest?
The option vests in full on the earlier of July 1, 2027 or Viridian Therapeutics’ (VRDN) 2027 annual meeting of stockholders. Vesting is conditioned on Christopher W. Cain’s continued service on the company’s Board of Directors through that vesting event.
Who benefits economically from the new VRDN option grant linked to director Cain?
Economic benefits from the option go to investment vehicles managed by Fairmount Funds Management LLC, not directly to Christopher W. Cain. Cain must turn over any net cash or stock from the option to Fairmount, and he disclaims beneficial ownership of the option and underlying shares.
Is the VRDN option grant an open-market purchase or a compensation award?
The transaction is a compensation-related option award, not an open-market purchase of Viridian Therapeutics (VRDN) shares. It was reported with code A as a grant or award acquisition, tied to board service, with no cash paid per share at the time of grant.
AI-generated analysis. How Rhea-AI works. Not financial advice.
